BRKR earnings analysis
What we found in BRKR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bruker reported Q1 2026 revenues of $823.4 million, exceeding expectations of $796.6 million, marking a 2.7% increase year-over-year. The company achieved a non-GAAP EPS of $0.31, while GAAP EPS was significantly lower at $0.02 amid increased operating expenses and lower operating income, which fell to $10.2 million, down from $31.8 million in the prior year. Management reaffirmed its FY2026 revenue guidance of between $3.57 billion and $3.60 billion, with an emphasis on organic growth of 1-2%.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q1 Revenue Increase
- Revenue rose to $823.4 million, a 2.7% increase from $801.4 million in Q1 2025.
- EPS Beat
- Non-GAAP EPS reported at $0.31, beating the expected $0.23 by 34.8%.
- Strong Operating Cash Flow
- Net cash provided by operating activities was $71.2 million, compared to $65.0 million in Q1 2025.
- Free Cash Flow Improvement
- Free cash flow increased to $47.0 million from $39.0 million in Q1 2025.
- Segment Growth in BSI CALID
- BSI CALID segment revenue increased by 12.9% to $316.3 million.
- Interest Income Surge
- Interest and other income grew significantly from -$6.7 million to $11.7 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Declining Operating Income
- Operating income decreased dramatically to $10.2 million from $31.8 million, down by 67.9% year-over-year.
- Increased Expenses
- Total operating expenses rose to $369.6 million, up from $359.4 million in Q1 2025.
- Foreign Exchange Headwinds
- Management cited foreign currency challenges impacting revenue and costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.31
- Gross margin
- 46.1%
- Operating margin
- 1.2%
- Segment
- BSI BioSpin: $197.5M, BSI CALID: $316.3M, BSI NANO: $246.0M, BEST: $66.8M
What they said about what is next.
Management reaffirmed FY2026 guidance, including organic growth of 1-2%.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BRKR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever